The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Leadership - Epcoritamab Global Council
Consulting or Advisory Role - Abbvie; Beigene; Bristol-Myers Squibb; Celgene; Genmab; Kite/Gilead; Roche
Speakers' Bureau - Abbvie; Celgene
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CellCentric (Inst); Genmab (Inst); Janssen (Inst); Kite/Gilead (Inst); MorphoSys (Inst); MSD (Inst); Nurix (Inst); Regeneron (Inst); Roche (Inst); Step Pharma (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
 
Yasmin Karimi
No Relationships to Disclose
 
Herve Ghesquieres
Honoraria - Gilead Sciences; Roche; Takeda
Consulting or Advisory Role - Gilead Sciences; Roche
Travel, Accommodations, Expenses - Abbvie
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche
Research Funding - Acerta Pharma; BeiGene; Epizyme; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics
 
Chan Cheah
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Novartis; Roche/Genentech; TG Therapeutics
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Merck; Roche/Genentech (Inst); TG Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche
 
Michael Clausen
Consulting or Advisory Role - Abbvie; Genmab; Janssen; Kite, a Gilead company
Speakers' Bureau - Abbvie; Janssen
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/Merck; Genmab; Janssen
 
Pieternella Lugtenburg
Consulting or Advisory Role - Abbvie; Celgene; Genmab; Incyte; Regeneron; Roche/Genentech; Takeda; Y-mAbs Therapeutics
Research Funding - SERVIER (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Celgene
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Young Rok Do
No Relationships to Disclose
 
David John Lewis
Consulting or Advisory Role - BeiGene; Janssen Oncology; Kite/Gilead
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Robin Gasiorowski
Honoraria - Abbvie; Astellas Pharma; Janssen; MSD; Novartis; Otsuka
 
Tae Min Kim
Consulting or Advisory Role - AstraZeneca/MedImmune; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda; Yuhan
Speakers' Bureau - IMBdx; Janssen Research & Development; Takeda
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Boryung; Novartis; Roche/Genentech
 
Marjolein van der Poel
Consulting or Advisory Role - Takeda
Travel, Accommodations, Expenses - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals
 
Michelle Li Mei Poon
No Relationships to Disclose
 
Tatyana A Feldman
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen; Takeda
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genmab; Seagen
Speakers' Bureau - Kite, a Gilead company; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Cell Medica (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Pfizer (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst); Viracta Therapeutics (Inst); Viracta Therapeutics (Inst)
Travel, Accommodations, Expenses - Seagen; Takeda
 
Kim M. Linton
No Relationships to Disclose
 
Anna Sureda
Honoraria - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Novartis; Takeda
Speakers' Bureau - Takeda
Travel, Accommodations, Expenses - Kite/Gilead
Other Relationship - Celgene; Gilead Sciences; Roche; Sanofi; Takeda
 
Martin Hutchings
Consulting or Advisory Role - Abbvie; Genmab; Janssen; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Genmab (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
 
Mariana Cota Stirner
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Mariana Sacchi
No Relationships to Disclose
 
Catherine Thieblemont
Honoraria - Abbvie; Bayer; Celgene; Gilead Sciences; Incyte; Janssen; Novartis; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Kite/Gilead; Novartis; Roche